New cell therapy for MS enters first human safety trial
Disease control
Not yet recruiting
This early-stage study tests whether a new cell therapy called universal STAR-T cells is safe for people with multiple sclerosis (MS). The trial will include 24 adults aged 18 to 65 with progressive or relapsing-remitting MS who have no other treatment options. Researchers will g…
Phase: PHASE1 • Sponsor: Daishi Tian • Aim: Disease control
Last updated May 15, 2026 11:56 UTC